

IN THE CLAIMS:

1. (Currently Amended) A pharmaceutical composition vaccine comprising:
a biocompatible carrier for injection or infusion, and pharmaceutical composition comprising
an isolated and purified N-terminal fragment of agglutinin like sequence (als1) cell surface adhesin
protein obtained from *Candida albicans*, wherein the vaccine produces an effective immune
response in a patient ~~to block adhesin of *Candida albicans* to endothelial cells.~~
2. (Cancelled)
3. (Currently Amended) The composition vaccine of Claim 1, wherein the protein ~~is an~~
~~N-terminal fragment and contains an~~ the adhesin binding site of *Candida albicans*.
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Currently Amended) The composition vaccine of claim 1 wherein the N-terminal
fragment is encoded by nucleotides 52 to 1296 of SEQ ID No.7 ~~protein is SEQ ID NO.7.~~